Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

radium-223 dichloride

- PMLiVE

EU clears AZ’s FDA-rejected diabetes combination

Approval of two-drug therapy Qtern presents first-to-market advantage in Europe

Deal Watch June 2016

Allergan, Novartis and Merck & Co are among those featured in this month's round-up of pharma deal activity

EU flag

European pharma ‘to grow 3.2% per year by 2022’

Forecast predicts AbbVie’s Humira will be knocked off the top spot

- PMLiVE

Pfizer set to snap up Bind’s assets for $20m

Biotech approves 'stalking horse' bid from the pharma giant

- PMLiVE

LEO Pharma picks up AZ skin disease drugs in $1bn deal

Gains rights to eczema and psoriasis treatments

- PMLiVE

US cuts at Boehringer hit sales force hardest

And Arena Pharmaceuticals plans US and Swiss 'reductions'

- PMLiVE

Tracking comms trends: Europe in the global vanguard on value

From multi-disciplinary teamwork to pharma’s reputation, value and access to global briefs, our contributors tackle some of the key topics in communications today

- PMLiVE

AZ gets EU green light for new antibiotic Zavicefta

EMA approves combination drug for treatment of multidrug resistant infections

China drug medicine pharma prices

Pfizer earmarks $350m for first Asian biotech facility

US pharma giant looks to tap into China’s pharmaceuticals market

Celgene building

NICE rejects Celgene’s Vidaza for leukaemia

Final draft guidance cites ‘high degree of uncertainty’ over clinical efficacy

- PMLiVE

CDC says no to AZ’s intranasal flu vaccine FluMist

US government data reports “poor” efficacy for the injected vaccine alternative

National Institute for Health and Care Excellence NICE logo

NICE backs five new drugs after discounts agreed

Includes Novartis’ previously rejected lung cancer and melanoma therapies Zykadia and Mekinist

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links